The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Inclusion Criteria:

1. Age: 18 to 75 years old, male or female;
2. Early or locally advanced breast cancer confirmed by pathology;
3. Lymph node positive or lymph node negative, ER and PR negative, T ≥ 2 or lymph nodenegative, ER positive or PR positive, T ≥ 5;
4. ECOG PS: 0-1; 5）Patients with low expression of HER-2: HER-2 IHC 1+or HER2 IHC 2+andISH negative;

Exclusion Criteria:

1. Stage IV breast cancer;
2. Have received anti-tumor treatment or radiotherapy for any malignant tumor in the pastfive years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma orsquamous cell carcinoma;
3. At the same time, other clinical trials have received anti-tumor therapy. If theresearcher judges that the patient cannot benefit from the researcher, otheranti-tumor therapy can be ended.
4. The patient has undergone major surgery unrelated to breast cancer within 4 weeksbefore enrollment, or has not fully recovered from such surgery;
5. Previously received ADC drugs, immunosuppressants, anti-HER2 and other treatments.